Cell Reprogramming Market Research Report Information By Technology (Sendai Virus-based Reprogramming, mRNA Reprogramming, Episomal Reprogramming, and Others), By Application (Research and Therapeutic), By End-use (Research & Academic Institutes and Biotechnology & Pharmaceutical Companies) –Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3.Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2.Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL CELL REPROGRAMMING MARKET, BY TECHNOLOGY

6.1. Overview

6.2. Sendai Virus-based Reprogramming

6.3. mRNA Reprogramming

6.4. Episomal Reprogramming

6.5. Others

7. GLOBAL CELL REPROGRAMMING MARKET, BY APPLICATION

7.1. Overview

7.2. Research

7.3. Therapeutic

8. GLOBAL CELL REPROGRAMMING MARKET, BY END-USE

8.1. Overview

8.2. Research & Academic Institutes

8.3. Biotechnology & Pharmaceutical Companies

9. GLOBAL CELL REPROGRAMMING MARKET, BY REGION

9.1. Overview

9.1. North America

9.1.1. US

9.1.2. Canada

9.2. Europe

9.2.1. Germany

9.2.2. France

9.2.3. UK

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. South Korea

9.3.5. Australia

9.3.6. Rest of Asia-Pacific

9.4. Rest of the World

9.4.1. Middle East

9.4.2. Africa

9.4.3. Latin America

10. COMPETITIVE LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Cell Reprogramming Market,

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global Cell Reprogramming Market,

10.7. Key developments and Growth Strategies

10.7.1. New Product Launch/Service Deployment

10.7.2. Merger & Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income, 2023

10.8.2. Major Players R&D Expenditure. 2023

11. COMPANY PROFILES

11.1. Lonza Group

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Thermo Fisher Scientific

11.2.1. Company Overview

11.2.2. Financial Overview

11.2.3. Products Offered

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Merck KGaA

11.3.1. Company Overview

11.3.2. Financial Overview

11.3.3. Products Offered

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Cellular Dynamics International

11.4.1. Company Overview

11.4.2. Financial Overview

11.4.3. Products Offered

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. STEMCELL Technologies Inc.

11.5.1. Company Overview

11.5.2. Financial Overview

11.5.3. Products Offered

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. ReproCELL Inc.

11.6.1. Company Overview

11.6.2. Financial Overview

11.6.3. Products Offered

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Takara Bio Inc.

11.7.1. Company Overview

11.7.2. Financial Overview

11.7.3. Products Offered

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Fate Therapeutics Inc.

11.8.1. Company Overview

11.8.2. Financial Overview

11.8.3. Products Offered

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. ViaCyte Inc

11.9.1. Company Overview

11.9.2. Financial Overview

11.9.3. Products Offered

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. BlueRock Therapeutics

11.10.1. Company Overview

11.10.2. Financial Overview

11.10.3. Products Offered

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL CELL REPROGRAMMING MARKET, SYNOPSIS, 2019-2032

TABLE 2 GLOBAL CELL REPROGRAMMING MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)

TABLE 3 GLOBAL CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 4 GLOBAL CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 5 GLOBAL CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 7 NORTH AMERICA: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 8 NORTH AMERICA: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 9 US: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 10 US: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 11 US: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 12 CANADA: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 13 CANADA: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 14 CANADA: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 1 EUROPE: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 2 EUROPE: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 3 EUROPE: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 4 GERMANY: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 5 GERMANY: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 6 GERMANY: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 7 FRANCE: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 8 FRANCE: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 9 FRANCE: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 10 ITALY: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 11 ITALY: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 12 ITALY: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 13 SPAIN: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 14 SPAIN: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 15 SPAIN: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 16 UK: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 17 UK: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 18 UK: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 19 REST OF EUROPE: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 20 REST OF EUROPE: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 21 REST OF EUROPE: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 22 ASIA-PACIFIC: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 23 ASIA-PACIFIC: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 24 ASIA-PACIFIC: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 25 JAPAN: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 26 JAPAN: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 27 JAPAN: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 28 CHINA: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 29 CHINA: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 30 CHINA: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 31 INDIA: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 32 INDIA: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 33 INDIA: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 34 AUSTRALIA: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 35 AUSTRALIA: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 36 AUSTRALIA: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 37 SOUTH KOREA: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 38 SOUTH KOREA: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 39 SOUTH KOREA: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 40 REST OF ASIA-PACIFIC: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 41 REST OF ASIA-PACIFIC: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 42 REST OF ASIA-PACIFIC: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 43 REST OF THE WORLD: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 44 REST OF THE WORLD: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 45 REST OF THE WORLD: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 46 MIDDLE EAST: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 47 MIDDLE EAST: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 48 MIDDLE EAST: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 49 AFRICA: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 50 AFRICA: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 51 AFRICA: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

TABLE 52 LATIN AMERICA: CELL REPROGRAMMING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)

TABLE 53 LATIN AMERICA: CELL REPROGRAMMING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

TABLE 54 LATIN AMERICA: CELL REPROGRAMMING MARKET, BY END-USE, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CELL REPROGRAMMING MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CELL REPROGRAMMING MARKET

FIGURE 4 GLOBAL CELL REPROGRAMMING MARKET, SHARE (%), BY TECHNOLOGY, 2023

FIGURE 5 GLOBAL CELL REPROGRAMMING MARKET, SHARE (%), BY APPLICATION, 2023

FIGURE 6 GLOBAL CELL REPROGRAMMING MARKET, SHARE (%), BY END-USE, 2023

FIGURE 7 GLOBAL CELL REPROGRAMMING MARKET, SHARE (%), BY REGION, 2023

FIGURE 8 NORTH AMERICA: CELL REPROGRAMMING MARKET, SHARE (%), BY REGION, 2023

FIGURE 9 EUROPE: CELL REPROGRAMMING MARKET, SHARE (%), BY REGION, 2023

FIGURE 10 ASIA-PACIFIC: CELL REPROGRAMMING MARKET, SHARE (%), BY REGION, 2023

FIGURE 11 REST OF THE WORLD: CELL REPROGRAMMING MARKET, SHARE (%), BY REGION, 2023

FIGURE 12 GLOBAL CELL REPROGRAMMING MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 13 LONZA GROUP: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 14 LONZA GROUP: SWOT ANALYSIS

FIGURE 15 THERMO FISHER SCIENTIFIC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 16 THERMO FISHER SCIENTIFIC: SWOT ANALYSIS

FIGURE 17 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 18 MERCK KGAA: SWOT ANALYSIS

FIGURE 19 CELLULAR DYNAMICS INTERNATIONAL: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 20 CELLULAR DYNAMICS INTERNATIONAL: SWOT ANALYSIS

FIGURE 21 STEMCELL TECHNOLOGIES INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 22 STEMCELL TECHNOLOGIES INC.: SWOT ANALYSIS

FIGURE 23 REPROCELL INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 REPROCELL INC.: SWOT ANALYSIS

FIGURE 25 TAKARA BIO INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 TAKARA BIO INC.: SWOT ANALYSIS

FIGURE 27 FATE THERAPEUTICS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 FATE THERAPEUTICS INC.: SWOT ANALYSIS

FIGURE 29 VIACYTE INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 VIACYTE INC: SWOT ANALYSIS

FIGURE 31 BLUEROCK THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 BLUEROCK THERAPEUTICS: SWOT ANALYSIS